Imunon, Inc. (IMNN) Stock Ticker
Market factors today
Unlock the full IMNN picture
About Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
IMNN stock facts
| Ticker symbol | IMNN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.9M |
| CEO | Stacy R. Lindborg |
| Employees | 20 |
| Headquarters | Lawrenceville, NJ, US |
| IPO date | 1999-03-01 |
| Website | www.imunon.com |
What you can see for IMNN on Tickr
Live IMNN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMNN report.
Rankings
FAQ
What is the ticker symbol for Imunon, Inc.?
The ticker symbol for Imunon, Inc. is IMNN, listed on the NASDAQ Capital Market.
What is IMNN?
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin,…